On this page
What is Aplastic Anemia?
Aplastic anemia, also known as bone marrow failure or, more precisely, aplastic anemia/aplastic syndrome, is a serious but treatable medical condition. In this condition, the bone marrow stops producing sufficient numbers of all three types of blood cells: red blood cells, white blood cells, and platelets. The term “aplastic” derives from the Greek word meaning “without formation”, a direct reference to the failure of the bone marrow to form adequate blood cells.
At the core of this condition is damage to hematopoietic stem cells within the bone marrow, the spongy, highly vascular tissue found in the interior cavities of certain bones. These stem cells are the biological foundation of the blood-forming system: they are self-renewing progenitor cells that can differentiate into all mature blood cell lineages. When they are damaged or destroyed, the bone marrow’s capacity to manufacture all types of blood cells is profoundly compromised. Aplastic anemia is therefore classified as a form of bone marrow failure, a category of conditions in which the marrow is unable to fulfill its primary biological function.
The most common underlying mechanism is autoimmune in nature: the body’s own immune system, through a process of aberrant activation, incorrectly identifies the hematopoietic stem cells as foreign or dangerous and mounts a destructive immune attack against them, as it would against an invading pathogen. This autoimmune mechanism is responsible for the majority of acquired cases. Less commonly, the cause may be a hereditary genetic disorder, exposure to toxic chemicals, viral infections, certain medications, radiation, or no identifiable cause can be found (idiopathic aplastic anemia) in a substantial proportion of cases.
Aplastic anemia can present in two broad clinical patterns:
- Acute (sudden) onset: Rapid development of symptoms over days to weeks
- Insidious (gradual) onset: Symptoms develop slowly over months
The severity varies considerably, from mild cases requiring only monitoring to severe or very severe cases threatening life.
The cardinal symptoms reflect the deficiency of all three blood cell types:
- Fatigue and easy fatigability: Due to anemia (insufficient red blood cells to carry oxygen)
- Increased susceptibility to infections: Due to leukopenia (insufficient white blood cells to fight pathogens)
- Easy bruising and bleeding tendency: Due to thrombocytopenia (insufficient platelets for blood clotting)
When left untreated, aplastic anemia can progress to life-threatening complications, including severe infections, uncontrolled hemorrhage, cardiac arrhythmias, and heart failure.
The treatment strategy is tailored to the severity of the condition, the patient’s age, and the underlying cause. With modern treatment, which includes immunosuppressive therapy and bone marrow transplantation, the prognosis is generally favorable, with many patients achieving durable remission and a good quality of life.
Physiology of Blood and Bone Marrow
To understand aplastic anemia, it is helpful to briefly review the normal biology of blood production, the process that this disorder fundamentally disrupts.
The Composition of Blood
Blood is a complex connective tissue comprising:
Plasma: The liquid component, which makes up approximately 55% of total blood volume, consists of water (around 92%). Dissolved in this water are proteins (such as albumin, clotting factors, and immunoglobulins), electrolytes, hormones, vitamins, nutrients, metabolic waste products, and dissolved gases. Plasma serves as the transport medium for both the cellular components of blood and the vast array of biological molecules that circulate throughout the body.
The cellular components:
Red Blood Cells (Erythrocytes): The most numerous blood cells, constituting approximately 40–45% of total blood volume (the hematocrit). Their primary function is oxygen transport: each red blood cell is packed with hemoglobin, an iron-containing protein with remarkable oxygen-binding capacity. Red blood cells pick up oxygen in the pulmonary capillaries, carry it through the systemic circulation to all tissues, and simultaneously transport carbon dioxide (the waste product of cellular metabolism) back to the lungs for exhalation. Red blood cells have a lifespan of approximately 120 days, after which they are cleared by the spleen and liver, and their components (including iron) are recycled.
White Blood Cells (Leukocytes): The cellular effectors of the immune system, present in much smaller numbers than red blood cells but absolutely essential for host defense. White blood cells encompass several distinct populations: neutrophils (the front-line defenders against bacterial infections), lymphocytes (T and B cells, which are responsible for adaptive immunity), monocytes (which differentiate into macrophages), eosinophils, and basophils. Each of these has specialized roles in recognizing, attacking, and eliminating infectious agents, cancer cells, and other threats.
Platelets (Thrombocytes): Not true cells but rather small anucleate fragments shed from large precursor cells called megakaryocytes in the bone marrow. Platelets are the first responders to vascular injury. They aggregate at sites of vessel wall damage, form the initial platelet plug, and activate the coagulation cascade, ultimately producing the fibrin clot that stops bleeding. Without adequate platelet numbers, even minor trauma can result in prolonged or uncontrolled hemorrhage.
The Process of Blood Cell Production: Hematopoiesis
The production of all blood cells is called hematopoiesis and occurs throughout life primarily in the bone marrow, the highly vascular, spongy tissue that fills the interior cavities of flat bones (sternum, ribs, vertebrae, pelvis, skull) and the epiphyseal ends of long bones (femur, humerus).
The entire hematopoietic system originates from a small population of hematopoietic stem cells (HSCs), which are rare, pluripotent cells with two defining properties:
- Self-renewal: The capacity to divide and produce daughter cells that retain stem cell identity, thereby maintaining the HSC pool throughout life
- Multipotency: The capacity to differentiate into all blood cell lineages when appropriate developmental signals are received
Under normal physiological conditions, HSCs continuously divide and differentiate through a series of progressively restricted progenitor stages, ultimately producing committed precursors for each blood cell lineage. As these precursors mature, acquiring their characteristic functions, surface markers, and structural features, they exit the bone marrow and enter the peripheral bloodstream. There, they replace older cells that have reached the end of their functional lifespan.
The rate of hematopoiesis is remarkable: a healthy adult produces approximately 500 billion blood cells per day to replace those that have aged out of circulation. This relentless production must be maintained continuously throughout life.
In aplastic anemia, this foundational process fails at its source: the stem cells themselves are damaged or destroyed, causing the bone marrow’s capacity to regenerate the blood cell population to collapse.
Causes
Aplastic anemia can affect individuals of any age, but epidemiological data suggest a bimodal age distribution, with peaks in young adults (between 15 and 25 years of age) and in older adults (over 60 years). It affects men and women equally. Some evidence suggests a higher incidence in populations of Asian ancestry.
Congenital (Inherited) Aplastic Anemia
A minority of cases result from inherited genetic disorders affecting the hematopoietic stem cell pool. These congenital forms typically manifest in the first decade of life. The most clinically important example is:
Fanconi Anemia: A rare autosomal recessive genetic disorder caused by mutations in any of the 22 known FANC genes, which are components of the Fanconi anemia DNA repair pathway. Cells lacking functional Fanconi anemia proteins are unable to efficiently repair specific types of DNA damage (particularly interstrand DNA crosslinks), leading to genomic instability and ultimately to HSC failure. Clinically, Fanconi anemia presents with progressive bone marrow failure (typically in the first or second decade of life), characteristic physical anomalies (short stature, thumb and radius abnormalities, skin hyperpigmentation, kidney malformations, and others), and a dramatically increased risk of malignancy (particularly acute myeloid leukemia and squamous cell carcinoma).
Other congenital syndromes associated with bone marrow failure include Dyskeratosis Congenita (caused by defects in telomere maintenance), Diamond-Blackfan Anemia (primarily affecting red blood cell production), and Shwachman-Diamond Syndrome.
Acquired Aplastic Anemia
The majority of aplastic anemia cases are acquired, developing after birth in individuals who did not inherit a predisposing genetic mutation. The principal causes include:
Autoimmune Destruction (Most Common Cause)
In the majority of acquired aplastic anemia cases, the underlying mechanism is an aberrant, autoreactive T-cell immune response directed against hematopoietic stem cells. For reasons not fully understood, cytotoxic T lymphocytes become activated and begin selectively destroying HSCs, as if they were foreign or dangerous. The inflammatory cytokines released during this process (particularly interferon-gamma and tumor necrosis factor) further suppress HSC function and survival.
This autoimmune mechanism explains why immunosuppressive therapy (treatments that dampen the immune system’s activity) is effective in restoring hematopoiesis in the majority of patients with acquired aplastic anemia.
Toxic Chemical Exposures
Several chemical agents are established causes of bone marrow toxicity:
- Benzene: A component of gasoline and industrial solvents; one of the most extensively documented bone marrow toxins. Occupational exposure in industries involving petroleum products, shoe manufacturing, rubber production, and chemical processing represents a significant risk.
- Pesticides and herbicides: Several agricultural chemicals have been associated with bone marrow suppression
- Arsenic: A heavy metal with recognized hematotoxic effects
Radiation Exposure
Radiation therapy directed to bone-bearing areas, and high-dose whole-body irradiation (as may occur in radiation accidents or nuclear events), can directly destroy hematopoietic stem cells. The bone marrow is among the most radiosensitive tissues in the body.
Chemotherapy
Chemotherapy agents, particularly alkylating agents and antimetabolites used in cancer treatment, suppress bone marrow function as a predictable, dose-dependent side effect. This is typically transient and reversible, though in some cases it can be prolonged or permanent.
Medications
Several pharmacological agents have been associated with idiosyncratic (unpredictable, non-dose-dependent) bone marrow suppression as a rare but serious adverse effect:
- Chloramphenicol: A broad-spectrum antibiotic now rarely used in developed countries precisely because of its association with aplastic anemia (estimated incidence approximately 1 in 25,000–40,000 treatment courses)
- Carbamazepine: An anticonvulsant and mood stabilizer
- Phenytoin: An anticonvulsant
- Sulfonamide antibiotics
- Gold compounds: Used historically in rheumatoid arthritis treatment
- Disease-modifying anti-rheumatic drugs (DMARDs): Including agents used for rheumatoid arthritis and systemic lupus erythematosus (SLE)
Viral Infections
Several viruses have been associated with triggering aplastic anemia, likely through direct HSC infection and/or by triggering the aberrant autoimmune response:
- Viral hepatitis: Seronegative hepatitis (hepatitis not attributable to known hepatitis viruses A, B, or C) is the most commonly identified viral trigger. This specific syndrome of hepatitis-associated aplastic anemia is a recognized and important clinical entity.
- Epstein-Barr virus (EBV): The causative agent of infectious mononucleosis; associated with aplastic anemia in some cases.
- Cytomegalovirus (CMV): A herpesvirus particularly dangerous in immunocompromised individuals.
- HIV: Can directly suppress bone marrow function through multiple mechanisms.
- Parvovirus B19: Selectively infects erythroid precursors; typically causes transient pure red cell aplasia rather than full aplastic anemia, but can produce severe marrow suppression in immunocompromised hosts.
Pregnancy
Aplastic anemia can, in rare cases, develop during pregnancy, likely through an immunologically mediated mechanism in which the maternal immune response to the pregnancy triggers cross-reactive autoimmune bone marrow suppression. Aplastic anemia complicating pregnancy is associated with significant risks for both mother and fetus.
Bone Marrow Infiltration by Malignancy
Metastatic cancer cells spreading from primary tumors (most commonly breast cancer, prostate cancer, or lymphoma) can invade and infiltrate the bone marrow, physically displacing and destroying the normal hematopoietic tissue and its stem cell population.
Idiopathic Aplastic Anemia
In a substantial proportion of acquired cases, estimated by some authorities at approximately 75% (3 in 4), no definitive underlying cause can be identified despite thorough investigation. These are classified as idiopathic aplastic anemia. It is believed that many idiopathic cases represent autoimmune processes in which the triggering event is not identifiable.
Symptoms
The clinical presentation of aplastic anemia directly reflects the quantitative deficiency of all three blood cell lineages, a condition called pancytopenia. The specific symptoms depend on which cell type is most severely reduced and the absolute severity of the deficiency.
Symptoms Due to Red Blood Cell Deficiency (Anemia)
The primary function of red blood cells is oxygen delivery to tissues. When their number is insufficient, tissues are deprived of adequate oxygen, producing the characteristic symptoms of anemia:
- Fatigue and easy fatigability: The most universal and often most debilitating symptom is that patients feel profoundly exhausted by minimal exertion.
- Difficulty concentrating and impaired attention: The brain is particularly sensitive to oxygen deprivation
- Loss of appetite and weight loss: Gastrointestinal symptoms related to reduced blood flow.
- Pallor: Visible paleness of the skin, lips, conjunctivae, and nail beds
- Shortness of breath (dyspnea): Particularly on exertion; even walking up stairs, carrying light objects, or other minimal activities may produce breathlessness.
- Palpitations and tachycardia: The heart compensates for reduced oxygen-carrying capacity by beating faster and harder.
- Decreased oxygen saturation: Measurable drop in peripheral oxygen saturation.
- Headache and dizziness: Consequences of reduced cerebral oxygen delivery.
- Cold intolerance: Reduced thermogenesis due to decreased tissue oxygenation.
Symptoms Due to White Blood Cell Deficiency (Leukopenia)
White blood cells, particularly neutrophils, are the body’s primary cellular defense against bacterial and fungal infections. When their numbers are severely reduced (neutropenia), the immune system cannot adequately respond to pathogens, leading to:
- Fever: Often the presenting sign of infection in a neutropenic patient. Fever in the context of known or suspected aplastic anemia should always be treated as a potential medical emergency.
- Recurrent, severe, or unusual infections:
- Urinary tract infections (cystitis): Producing burning with urination and increased urinary frequency.
- Pneumonia and lung infections: Producing cough and respiratory difficulty.
- Oral infections: Mouth ulcers and aphthous stomatitis, which are painful sores on the oral mucosa.
- Sinusitis: Facial pain, nasal discharge.
- Skin infections: Cellulitis, boils, abscesses.
- Fungal infections: In severely neutropenic patients, normally non-pathogenic fungi (such as Aspergillus and Candida) can cause life-threatening invasive infections.
The critical clinical danger of severe neutropenia is that the inflammatory response to infection is itself blunted. Patients may have serious systemic infections with minimal or atypical signs. Without a functioning immune system, even common community-acquired infections can rapidly become life-threatening.
Symptoms Due to Platelet Deficiency (Thrombocytopenia)
Platelets are essential for normal blood clotting. When platelet counts are severely reduced (thrombocytopenia), the ability to form an adequate clot at sites of vessel injury is compromised, resulting in abnormal bleeding:
- Unexplained bruising (ecchymoses): Large, easily provoked bruises appearing from minimal or unrecognized trauma
- Epistaxis (nosebleeds): Often the first noticeable bleeding symptom.
- Gingival bleeding: Gums that bleed spontaneously or with minimal provocation.
- Heavy menstrual bleeding (menorrhagia): Often dramatically increased in affected women.
- Petechiae: Tiny pinpoint red or purple spots on the skin, representing minute hemorrhages from capillaries. This is a specific and diagnostically important sign of severe thrombocytopenia.
- Prolonged bleeding from cuts and minor wounds.
- Blood in urine (hematuria) or stool (hematochezia).
- Internal hemorrhage: In severe thrombocytopenia, there is a risk of dangerous intracranial hemorrhage (bleeding into the brain), which can be life-threatening.
Complications
Without timely diagnosis and appropriate treatment, aplastic anemia can progress to produce serious and potentially life-threatening complications:
Severe Infections
In the setting of severe neutropenia, bacterial, fungal, and viral infections can rapidly overwhelm the compromised immune system. Septicemia (systemic bloodstream infection) is a leading cause of death in untreated aplastic anemia. Fungal pneumonia, particularly invasive aspergillosis, is an especially feared complication in severely neutropenic patients.
Uncontrolled Hemorrhage
Severe thrombocytopenia creates risk for spontaneous hemorrhage into critical locations. Intracranial hemorrhage (bleeding into the brain) is the most feared hemorrhagic complication, a potentially fatal event. Gastrointestinal hemorrhage and other internal bleeding events also represent significant threats.
Cardiac Complications
Severe, prolonged anemia imposes chronic hemodynamic stress on the heart:
- Cardiac arrhythmias: Irregular heart rhythms provoked by myocardial hypoxia (insufficient oxygen delivery to the heart muscle).
- Pathological cardiac enlargement (cardiomegaly): The heart hypertrophies as it works harder to maintain tissue oxygenation.
- Heart failure: The decompensated end-stage of chronic cardiac overload from severe anemia.
Malignant Transformation
Patients with aplastic anemia, particularly those treated with immunosuppressive therapy rather than bone marrow transplantation, have a higher than expected long-term risk of developing:
- Clonal hematopoietic disorders: Including paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML).
- This risk is related to the underlying biological instability of the hematopoietic stem cell pool and the selective pressures created by immunosuppression.
- Long-term follow-up and periodic blood count monitoring are essential for all aplastic anemia patients following treatment.
Psychosocial Consequences
The chronic nature of aplastic anemia, the treatment demands (hospital admissions, transfusions, the bone marrow transplantation process), the infectious risks, and the uncertainty of prognosis impose significant psychological burden on patients and their families. Depression, anxiety, and reduced quality of life are common and should be proactively assessed and managed.
Diagnosis
The diagnosis of aplastic anemia involves a structured sequence of investigations aimed at confirming the diagnosis, establishing its severity, identifying the underlying cause where possible, and guiding treatment decisions.
Clinical Presentation and Initial Suspicion
Aplastic anemia is typically suspected when a patient presents with:
- Symptoms attributable to pancytopenia (fatigue, breathlessness, infections, bleeding tendency).
- Incidental discovery of pancytopenia on a routine complete blood count (CBC/emocromo) performed for another indication.
Complete Blood Count (CBC) with Differential
The CBC is the critical first investigation and reveals the characteristic pancytopenia:
- Low hemoglobin (anemia).
- Low white blood cell count, with a disproportionate reduction in neutrophils (the absolute neutrophil count, or ANC, is a key severity parameter).
- Low platelet count (thrombocytopenia).
The CBC is interpreted alongside the peripheral blood smear, a microscopic examination of the blood that provides information about the morphology (size, shape, appearance) of cells. In aplastic anemia, the cells that are present typically appear morphologically normal. The problem is that there are too few of them, not that they are structurally abnormal (unlike other anemias, such as iron deficiency or megaloblastic anemia).
Severity Classification
Aplastic anemia is classified into severity categories that guide treatment decisions:
- Moderate aplastic anemia: Hypocellular bone marrow with blood count depression not meeting severe or very severe criteria
- Severe aplastic anemia (SAA): Bone marrow cellularity <25% (or 25–50% with <30% residual hematopoietic cells) plus at least 2 of 3 peripheral blood criteria: ANC <500/μL, platelet count <20,000/μL, reticulocyte count <20,000/μL
- Very severe aplastic anemia (vSAA): Meeting SAA criteria but with ANC <200/μL
Differential Diagnostic Investigations
Before confirming aplastic anemia, other causes of pancytopenia must be systematically excluded:
Reticulocyte count: Measures the number of newly produced, immature red blood cells, which is a direct index of bone marrow erythroid output. In aplastic anemia, reticulocytes are characteristically very low (reflecting the absence of effective marrow production), distinguishing it from hemolytic anemias where reticulocytes are elevated.
Erythropoietin (EPO) level: The kidney-produced hormone that stimulates red blood cell production in response to hypoxia. In aplastic anemia, EPO levels are typically markedly elevated. The kidneys are sending maximum production signals, but the bone marrow cannot respond.
Iron studies: Serum iron, ferritin, transferrin, and total iron-binding capacity. These tests help exclude iron-deficiency anemia, which is the most common cause of anemia globally but produces a very different clinical and laboratory picture.
Vitamin B12 and folate levels: Deficiency of either produces megaloblastic anemia, which is a macrocytic anemia (large red blood cells) with bone marrow changes that can superficially resemble aplastic anemia. Both are easily treatable when identified.
Thyroid function tests: Hypothyroidism can cause macrocytic anemia.
Autoatomic markers: Antinuclear antibodies (ANA), anti-dsDNA antibodies, and complement levels help identify underlying autoimmune conditions, such as systemic lupus erythematosus (SLE), that can cause bone marrow suppression.
Viral serology: Hepatitis A, B, and C; EBV; CMV; HIV; parvovirus B19 (to identify viral triggers).
Ham’s test / Flow cytometry for PNH clone: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal disorder closely related to aplastic anemia. Flow cytometric identification of GPI-anchor-deficient cells (CD55 and CD59 negative red blood cells and neutrophils) detects even small PNH clones.
Chromosomal breakage testing (for suspected Fanconi anemia): When a hereditary cause is suspected, particularly in children, adolescents, and young adults, or when physical stigmata suggest Fanconi anemia, chromosomal breakage testing (exposing lymphocytes to DNA cross-linking agents such as diepoxybutane or mitomycin C) provides the definitive functional diagnosis.
Bone Marrow Aspiration and Biopsy: The Definitive Diagnostic Test
The definitive diagnosis of aplastic anemia is established through bone marrow aspiration and biopsy, a procedure in which a small sample of bone marrow tissue and cellular material is obtained (typically from the posterior iliac crest (hip bone)) under local anesthesia and examined microscopically.
Bone marrow aspiration: A needle is inserted into the marrow cavity and liquid marrow is aspirated, allowing examination of individual cell morphology and differential counting of marrow cells.
Bone marrow core biopsy: A small cylinder of solid bone marrow tissue is removed, processed histologically, and sectioned, allowing assessment of marrow architecture and cellularity (the proportion of the marrow space occupied by hematopoietic cells versus fat).
In aplastic anemia, the characteristic findings are:
- Markedly hypocellular bone marrow: The normally cell-rich marrow (60–70% cellular in young adults) is replaced by empty fatty spaces, often described as a “desert” or “empty” marrow on biopsy.
- Dramatically reduced or absent hematopoietic precursors across all cell lineages.
- Preserved marrow architecture without evidence of fibrosis, malignant infiltration, or dysplasia (which would suggest alternative diagnoses).
- Normal morphology of residual cells: The few remaining cells appear structurally normal, again distinguishing aplastic anemia from myelodysplastic syndrome, where morphological dysplasia is the hallmark.
Additional investigations including cytogenetics (chromosome analysis of marrow cells) and flow cytometry may be performed on the bone marrow sample to exclude myelodysplastic syndrome, leukemia, and other hematological malignancies that can occasionally mimic aplastic anemia.
Treatment
The treatment approach for aplastic anemia is guided by several key factors: the severity of the condition (moderate, severe, or very severe), the patient’s age, the availability of a matched sibling donor, and the underlying cause where identifiable. The overarching goals are to restore normal hematopoiesis, prevent and treat complications, and achieve durable remission.
Supportive Care
Supportive care measures are initiated promptly in all patients, regardless of severity, and maintained throughout definitive treatment:
Prevention and Treatment of Infection:
- Protective isolation: Particularly in severely neutropenic patients, single rooms, HEPA-filtered air, and meticulous hand hygiene by all contacts are required.
- Prophylactic antimicrobials: Antifungal prophylaxis (fluconazole or posaconazole), antibacterial prophylaxis in high-risk periods, antiviral prophylaxis in patients receiving immunosuppression
- Prompt empiric antibiotic therapy: Any fever in a severely neutropenic patient is treated as a hematological emergency; broad-spectrum IV antibiotics are started immediately without waiting for culture results.
Blood Transfusions:
- Red blood cell transfusions: To correct symptomatic anemia, improve oxygen saturation, and relieve the cardiovascular burden of chronic anemia.
- Platelet transfusions: To raise platelet counts above the threshold for spontaneous hemorrhage (typically <10,000/μL) or to cover procedures and bleeding episodes.
- Transfusions are carefully managed to avoid alloimmunization, the development of antibodies against donor blood cell antigens that can complicate future bone marrow transplantation. Leukodepleted and irradiated blood products are used.
Growth Factors:
- Granulocyte colony-stimulating factor (G-CSF): Stimulates neutrophil production and can help bridge patients through high-risk infectious periods
- Erythropoiesis-stimulating agents (ESAs): To support red blood cell production in appropriate patients
- Thrombopoietin receptor agonists: Drugs that stimulate platelet production have shown promise in aplastic anemia (eltrombopag has received regulatory approval as an adjunct to immunosuppressive therapy)
Definitive Treatment: Bone Marrow Transplantation
Bone marrow transplantation (BMT) / Hematopoietic stem cell transplantation (HSCT) is the gold-standard curative treatment for severe and very severe aplastic anemia. It is also the preferred treatment option for younger patients (typically under 40 years of age) with a well-matched sibling donor.
The transplantation process involves:
-
Donor selection: The ideal donor is an HLA (Human Leukocyte Antigen)-matched sibling, a brother or sister sharing the same HLA tissue type. HLA matching is critical to minimize the risk of graft rejection (the recipient’s remaining immune cells attacking the donor cells) and graft-versus-host disease (GVHD, where donor immune cells attack recipient tissues).
-
Conditioning regimen: The recipient undergoes a preparatory regimen of immunosuppressive and/or myelosuppressive therapy, typically using cyclophosphamide with or without antithymocyte globulin (ATG), to destroy remaining abnormal immune cells that caused the aplasia and create “space” in the marrow for engraftment.
-
Stem cell infusion: Hematopoietic stem cells from the donor, which are collected either from the donor’s bone marrow (under general anesthesia) or from peripheral blood (following G-CSF mobilization), are infused intravenously as a blood transfusion.
-
Engraftment: Donor stem cells migrate to the bone marrow, establish themselves, and begin producing all blood cell lineages. Full engraftment typically requires several weeks to months.
When a matched sibling donor is available and the patient is young, BMT offers cure rates exceeding 80–90% in the best centers. The major complications of BMT include graft failure, GVHD (which can range from mild to life-threatening), serious infections during the neutropenic period following transplantation, and organ toxicity from the conditioning regimen.
For patients without a matched sibling donor, alternative donor sources are available, including well-matched unrelated donors (identified through international bone marrow donor registries), haploidentical donors (partially matched family members, typically parents or children), and umbilical cord blood units. Outcomes with these alternative donor transplants have improved substantially with advances in conditioning regimens and GVHD prophylaxis, though they generally remain somewhat inferior to matched sibling transplants.
Immunosuppressive Therapy (IST)
For patients who are not candidates for bone marrow transplantation, typically because they are older than 40, do not have a matched sibling donor, or have medical comorbidities that preclude the transplant procedure, immunosuppressive therapy is the primary treatment.
The standard IST regimen combines:
- Anti-thymocyte globulin (ATG): A preparation of antibodies against human T lymphocytes (the immune cells responsible for destroying HSCs), derived from horses (horse-ATG, hATG) or rabbits (rabbit-ATG, rATG). ATG rapidly depletes the autoreactive T-cell population, removing the immunological attack on stem cells and allowing HSC recovery.
- Cyclosporine A: A calcineurin inhibitor that suppresses T-cell activation and cytokine production. It is given orally for an extended period, typically 1–2 years, following ATG to prevent relapse.
- Eltrombopag: A thrombopoietin receptor agonist that not only stimulates platelet production but also appears to directly stimulate HSC activation and proliferation. Its addition to the standard ATG + cyclosporine backbone has been shown in randomized trials to significantly improve response rates and is now increasingly incorporated into first-line IST protocols.
- Growth factor support (G-CSF) during the initial treatment period
Response to IST: Approximately 60–70% of patients respond to first-line IST with recovery of blood counts sufficient for transfusion independence. Responses develop gradually over 3 to 6 months. Relapse occurs in 30–40% of responders, often treatable with a second course of IST or transition to transplantation.
Long-term follow-up after IST is essential: Patients successfully treated with IST require lifelong monitoring for late clonal complications, particularly evolution to PNH, myelodysplastic syndrome, or acute leukemia.
Treatment of Specific Underlying Causes
When aplastic anemia is caused by a specific identifiable trigger, addressing that cause is an essential component of management:
- Discontinuing the offending medication: If a drug-induced cause is identified
- Treating the underlying viral infection: Where possible
- Managing pregnancy-related aplasia: With appropriate support and specialist involvement
- Removing toxic exposures: Where occupational or environmental toxins are identified
Prognosis and Long-Term Outlook
The prognosis of aplastic anemia has improved dramatically over the past four decades with advances in bone marrow transplantation techniques, improvements in immunosuppressive regimens, better supportive care, and the availability of broader donor pools.
With appropriate treatment, the overall prognosis is generally favorable:
- Bone marrow transplantation from a matched sibling: Long-term survival rates of 80–90% in younger patients (<20 years), with excellent long-term quality of life in survivors
- Immunosuppressive therapy: Overall response rates of 60–70%; long-term survival of approximately 70–80%, with some patients achieving durable remission while others require additional treatment courses
- Older patients and unrelated donor transplants: Somewhat lower overall survival, though outcomes continue to improve with evolving protocols
Without treatment, severe aplastic anemia carries a very poor prognosis. Historically, over 70% of patients with severe disease died within one year of diagnosis.
Long-term survivors of aplastic anemia require ongoing hematological monitoring for:
- Relapse of aplastic anemia (in IST-treated patients)
- Clonal evolution to PNH (a related clonal disorder)
- Transformation to myelodysplastic syndrome or acute leukemia
- Late effects of transplantation (chronic GVHD, secondary malignancies, endocrine dysfunction)
Frequently Asked Questions
What is the difference between aplastic anemia and ordinary anemia?
Ordinary anemia refers specifically to a reduction in red blood cell count or hemoglobin concentration. It affects only one blood cell lineage and has many different causes, such as iron deficiency, vitamin B12 deficiency, chronic disease, and blood loss. Aplastic anemia is a much more serious and rarer condition in which the bone marrow fails to produce all three blood cell types (red cells, white cells, and platelets) simultaneously (pancytopenia), due to destruction or dysfunction of hematopoietic stem cells. It is not simply “severe anemia” but a form of bone marrow failure with distinct causes, mechanisms, and treatments.
Is aplastic anemia curable?
Yes, in many patients, aplastic anemia can be effectively treated and even cured. For younger patients with a matched sibling donor, bone marrow transplantation offers cure rates exceeding 80%. For older patients or those without a suitable donor, immunosuppressive therapy produces sustained remission in the majority of patients, though relapse is possible. Even patients who relapse can often be re-treated successfully.
How is aplastic anemia diagnosed?
The definitive diagnosis requires a bone marrow biopsy, a procedure in which a small sample of bone marrow tissue is obtained from the hip bone and examined microscopically. The hallmark finding is a dramatically hypocellular marrow with few or no hematopoietic cells. Blood tests showing pancytopenia (low red cells, white cells, and platelets) initially raise the suspicion, and additional tests are performed to rule out other causes before proceeding to biopsy.
Who is most at risk?
Aplastic anemia has a bimodal incidence, being most common in young adults (15–25 years) and in older adults (over 60 years). It appears to be somewhat more common in individuals of East Asian ancestry. Specific risk factors include certain medication exposures, viral infections, chemical exposures (benzene, pesticides), and radiation. In children, congenital causes (such as Fanconi anemia) should always be considered.
Can aplastic anemia recur after treatment?
Yes, relapse is possible, particularly after immunosuppressive therapy; it occurs in 30–40% of initial responders. Relapse is generally less common after bone marrow transplantation (which provides a new, healthy immune and hematopoietic system). Patients who relapse after IST may respond to a second IST course or proceed to bone marrow transplantation if not previously transplanted. Regular blood count monitoring after treatment is essential to detect relapse early.
Sources and Bibliography
- NIH – National Heart, Lung, and Blood Institute: Aplastic Anemia
- MSD Manual Professional Edition: Aplastic Anemia
- Aplastic Anemia & MDS International Foundation (AAMDS)
- Killick SB, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. British Journal of Haematology, 2016.
- Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology (ASH Education Program), 2012.
- Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood, 2006.
- Dezern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Review of Hematology, 2011.
- Townsley DM, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. New England Journal of Medicine, 2017.
- European Group for Blood and Marrow Transplantation (EBMT): Guidelines for treatment of aplastic anemia.
- Alter BP. Fanconi anemia and the development of leukemia. Best Practice & Research Clinical Haematology, 2014.
